Lexaria Bioscience Corp. provided an update on May 12, 2025, regarding its Material Transfer Agreement (MTA) with a pharmaceutical company, initially announced on September 3, 2024. Initial preclinical studies, which examined pharmacokinetics in animals, have been performed under the MTA.
Lexaria reported that the pharmaceutical company wishes to review the pending safety (adverse events) and efficacy data from Lexaria's ongoing independent human study GLP-1-H24-4 in Australia. This data is expected to become available beginning in Q3 2025.
The parties have agreed to continue their relationship under the MTA, keeping the temporary exclusive license active. Lexaria is preparing for strategic planning discussions with the pharmaceutical company's human clinical development team, indicating the possibility of future collaborative human clinical studies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.